Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics · Stress-induced childhood-onset neurodegeneration with ataxia and seizures

Understanding Your Child's Test Results and Diagnosis

At a Glance

CONDSIAS is usually confirmed by finding two disease-causing changes in the ADPRHL2 gene, supported by a child's symptoms and testing. Brain MRI, EEG, and nerve studies can show effects, but normal or variable results do not rule it out.

Confirming a diagnosis of CONDSIAS (Stress-induced childhood-onset neurodegeneration with ataxia and seizures) is a multi-step process that combines genetic results with physical clues found in the brain and nerves. Because this condition is ultra-rare and its symptoms can mimic other disorders, your doctor likely used several different types of tests to reach this conclusion [1][2].

Genetic Testing: Finding the Blueprint

The most important step in diagnosing CONDSIAS is identifying changes in the ADPRHL2 (or ADPRS) gene. Routine blood tests and metabolic screens are often normal or nonspecific in children with this condition, which is why advanced genetic testing is necessary [3][2].

  • Whole Exome Sequencing (WES): This is the most common test used to find CONDSIAS. It scans the “coding” parts of all your genes to look for errors [2][4]. WES can sometimes miss repeat expansions or deep intronic variants.
  • Whole Genome Sequencing (WGS): If WES is negative but doctors still suspect a genetic cause, they may use WGS, which looks at the entire DNA sequence including non-coding regions, or they may use copy-number analysis [5][6].
  • Trio Testing: Geneticists prefer to test the child and both parents at the same time. This helps them confirm that the child inherited one variant from each parent (called being in trans) and helps identify de novo variants, improving interpretation [7][2].

Reading the Genetic Report

When you look at your child’s genetic report, you are looking for specific terms that support the diagnosis. A diagnosis of CONDSIAS usually involves:

  1. Biallelic Variants: This means there are two changes found in the ADPRHL2 gene. They can be homozygous (two copies of the exact same error) or compound heterozygous (two different errors in the same gene) [1][8].
  2. Pathogenic or Likely Pathogenic: These terms mean the laboratory is confident that the genetic change is actually causing a problem with the enzyme [1][9]. If the report says VUS (Variant of Uncertain Significance), more evidence is needed to prove it causes the disease, and it should not guide treatment without expert review [10][11].
  3. Segregation Confirmed: The report may note that parental testing was done to prove the child inherited one variant from each parent. A report without this is not necessarily invalid, but it is a helpful piece of evidence [2][12].

Imaging and Electrical Testing

While genetic testing provides the “why,” imaging and electrical tests show the “how”—specifically, how the condition may be affecting your child’s body [13]. A normal result does not necessarily rule out the condition, as findings are variable.

Brain MRI (Neuroimaging)

The MRI is used to look at the structure of the brain. In CONDSIAS, variable findings include:

  • Cerebellar Atrophy: The cerebellum (the balance center of the brain) may appear smaller than normal [4][3].
  • White Matter Changes: Doctors may see signal changes in the “white matter” pathways [2].
  • Progression: In some children, these changes are stepwise, appearing or worsening over time [2].

EEG (Brain Waves)

An EEG records the electrical activity of the brain. A routine EEG can be normal even with epilepsy, but it may also show generalized abnormal activity or focal seizures (seizures starting in one specific part of the brain) [2][9].

Nerve Conduction Studies

Because CONDSIAS can cause weakness and numbness in the hands and feet, doctors may perform a nerve conduction study to assess nerve damage. This test sometimes shows axonal polyneuropathy, meaning the “wires” (axons) of the peripheral nerves are damaged [13][14].

Test Type Reported/Variable Findings in CONDSIAS
Genetic Test Two pathogenic variants in ADPRHL2 [1]
Brain MRI Atrophy of the cerebellum and/or cerebrum; white matter changes [2]
EEG Epileptiform discharges, focal seizures or general abnormal electrical activity [2]
Nerve Study Axonal neuropathy (damage to the long fibers of the nerves) [13]

Common questions in this guide

What genetic test is usually used to diagnose CONDSIAS?
Whole exome sequencing, or WES, is commonly used because it checks the protein-coding parts of many genes, including ADPRHL2. If WES does not find an answer but suspicion remains, clinicians may consider whole genome sequencing or copy-number analysis.
Why are both parents tested with their child for CONDSIAS?
Trio testing compares the child's results with results from both parents. It can show whether the child inherited one ADPRHL2 variant from each parent and can help identify a new change that was not inherited.
What do two pathogenic ADPRHL2 variants mean?
They mean the laboratory found two ADPRHL2 changes considered capable of causing disease. The changes may be identical or different, and the result is interpreted together with the child's symptoms and other clinical findings.
What does a VUS mean in my child's genetic report?
A variant of uncertain significance, or VUS, is a genetic change for which there is not enough evidence to know whether it causes disease. It should not be used by itself to make treatment decisions; a genetics expert may review family testing and other evidence as it becomes available.
Can a normal MRI or EEG rule out CONDSIAS?
A normal MRI or EEG does not necessarily rule out CONDSIAS. MRI changes are variable, and a routine EEG can be normal even when a child has epilepsy, so clinicians consider the full clinical picture and genetic results.
What does axonal neuropathy mean for my child's walking?
Axonal neuropathy means that the long nerve fibers outside the brain and spinal cord are damaged. It can contribute to weakness or numbness in the hands and feet and may affect walking, but the impact varies from child to child and should be assessed by the care team.

Get notified when new evidence is published on Childhood-onset stress-induced neurodegenerative ataxia-seizure syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    CONDSIAS, a Stress-Triggered Childhood Neurodegeneration: Four Novel ADPRS Variants and a Structured Review of the Reported Phenotype.

    Comisi FF, Staccioli S, Travaglini L, et al.

    Cerebellum (London, England) 2026; (25(6)).

    PMID: 42986566
  2. 2

    Novel imaging and clinical phenotypes of CONDSIAS disorder caused by a homozygous frameshift variant of ADPRHL2: a case report.

    Aryan H, Razmara E, Farhud D, et al.

    BMC neurology 2020; (20(1)):291 doi:10.1186/s12883-020-01873-3.

    PMID: 32746785
  3. 3

    Child-Onset Cerebellar Ataxia Caused by Two Compound Heterozygous Variants in ADPRS Gene: A Case Report.

    Ma J, Qian Q, Yan S, et al.

    Frontiers in genetics 2021; (12()):788702 doi:10.3389/fgene.2021.788702.

    PMID: 35664652
  4. 4

    Expanding the Spectrum of Stress-Induced Childhood-Onset Neurodegeneration with Variable Ataxia and Seizures (CONDSIAS).

    Lindskov FO, Karlsson WK, Skovbølling SL, et al.

    Cerebellum (London, England) 2024; (23(2)):861-871 doi:10.1007/s12311-023-01582-w.

    PMID: 37392332
  5. 5

    Beyond the exome: utility of long-read whole genome sequencing in exome-negative autosomal recessive diseases.

    AlAbdi L, Shamseldin HE, Khouj E, et al.

    Genome medicine 2023; (15(1)):114 doi:10.1186/s13073-023-01270-8.

    PMID: 38098057
  6. 6

    Whole genome sequencing for copy number variant detection to improve diagnosis and management of rare diseases.

    Bowman P, Grimes H, Dallosso AR, et al.

    Developmental medicine and child neurology 2025; (67(1)):126-131 doi:10.1111/dmcn.15985.

    PMID: 38840441
  7. 7

    Diagnostic yield of 1000 trio analyses with exome and genome sequencing in a clinical setting.

    Malmgren H, Kvarnung M, Gustafsson P, et al.

    Frontiers in genetics 2025; (16()):1580879 doi:10.3389/fgene.2025.1580879.

    PMID: 40620702
  8. 8

    Case Report: Stress-Induced Childhood-Onset Neurodegeneration With Ataxia-Seizures Syndrome Caused by a Novel Compound Heterozygous Mutation in ADPRHL2.

    Lu A, Dong C, Chen B, et al.

    Frontiers in neurology 2022; (13()):807291 doi:10.3389/fneur.2022.807291.

    PMID: 35222245
  9. 9

    Novel heterozygous variant of ADPRHL2 causes pathogenic variation in CONDSIAS.

    Yan S, Ren J, Su H, et al.

    Heliyon 2024; (10(14)):e32945 doi:10.1016/j.heliyon.2024.e32945.

    PMID: 39100487
  10. 10

    Clinical and functional characterization of a novel homozygous non-canonical splice mutation (c.1910-15_1910-11delinsTTACA) in CEP290 causing Joubert syndrome.

    Kovalskaia VA, Maslennikov DN, Svirepova KA, et al.

    Human genomics 2026; (20(1)).

    PMID: 42271513
  11. 11

    Novel ADPRS Missense Variant (p.Leu162Pro) Causes Stress-Induced Childhood-Onset Neurodegeneration With Ataxia and Seizures.

    de Mattos PD, de Moura RD, Bertolino MF, et al.

    Neurology. Genetics 2026; (12(3)):e200375 doi:10.1212/NXG.0000000000200375.

    PMID: 42015965
  12. 12

    Novel Compound Heterozygous Mutations in the TRAPPC9 Gene in Two Siblings With Autism and Intellectual Disability.

    Hnoonual A, Graidist P, Kritsaneepaiboon S, Limprasert P

    Frontiers in genetics 2019; (10()):61 doi:10.3389/fgene.2019.00061.

    PMID: 30853973
  13. 13

    Delineation of ADPRHL2 Variants: Report of Two New Patients with Review of the Literature.

    Öz Yıldız S, Yalnızoğlu D, Şimsek Kiper PÖ, et al.

    Neuropediatrics 2024; (55(3)):156-165 doi:10.1055/s-0044-1779618.

    PMID: 38365196
  14. 14

    Infantile-Onset Charcot-Marie-Tooth Disease With Pyramidal Features and White Matter Abnormalities Due to a De novo MORC2 Gene Variant: A Case Report and Brief Review of the Literature.

    Frongia I, Rizzi S, Baga M, et al.

    Frontiers in neurology 2021; (12()):718808 doi:10.3389/fneur.2021.718808.

    PMID: 34630290

This page is for educational and informational purposes only and does not constitute medical advice. Your child's geneticist, neurologist, and other clinicians should interpret CONDSIAS test results and recommend care for your child.